Lung Cancers Completed Phase 1 / 2 Trials for Erlotinib (DB00530)

Also known as: LUng Cancer / Cancer, Lung / Lung neoplasm malignant / Lung cancer NOS / Cancer of lung / Ca lung

IndicationStatusPhase
DBCOND0072929 (Lung Cancers)Completed1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02155465Trial of Ruxolitinib and Erlotinib in Patients With EGFR-mutant Lung Adenocarcinoma With Acquired Resistance to ErlotinibTreatment
NCT00390429Docetaxel and Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid TumorsTreatment
NCT01068587MET/VEGFR2 Inhibitor GSK1363089 and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer That Has Not Responded to Previous ChemotherapyTreatment
NCT01302808Romidepsin and Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Non-Small Cell Lung CancerTreatment
NCT00826449Dasatinib and Erlotinib in Non-Small Cell Lung Cancer (NSCLC)Treatment
NCT00387322Pemetrexed Disodium and Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid TumorsTreatment
NCT00280150Combination Chemotherapy, Bev, RT, and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung CancerTreatment
NCT00043823Avastin and Tarceva for Locally Advanced or Metastatic Non-Squamous Non-Small-Cell Lung CancerTreatment